Karyopharm Therapeutics Inc

This study tests an experimental drug called selinexor in adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who have run out of standard treatments. The main goal is to see how many patients respond to the drug. About 244 participants will …

This study tests whether adding the drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot have a stem cell transplant or CAR-T therapy. About 500 participants will receive either the new combination or…

This study tests a drug called selinexor combined with other standard treatments for multiple myeloma, a type of blood cancer. It includes 300 adults with either newly diagnosed or relapsed/refractory disease. The goal is to find safe doses and see how well the combinations contr…

This study was designed to test the safety and effectiveness of combining the drug selinexor with other treatments for people whose diffuse large B-cell lymphoma had returned or stopped responding to therapy. It planned to enroll adults aged 18 and older who had already received …

This study tests a drug called selinexor against the doctor's choice of treatment for people with myelofibrosis, a rare bone marrow disorder. Participants must have already tried a JAK inhibitor for at least 6 months. The main goal is to see if selinexor can shrink the spleen and…

This study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow cancer. About 353 adults with moderate-to-high risk disease who have not had prior treatment will take pa…